TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable coronary artery disease scheduled for elective percutaneous coronary intervention~Exclusion Criteria:~* Patients with acute coronary syndrome, patients with an MI within 30 days, an ejection fraction \<30%, those with history of IV Dye allergy, creatinine level\>2.2, those with increased risk of infection, those with history of bleeding diathesis or anemia (hemoglobin\<11.0 g/dl, platelets \<100,000 tho/ul)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 Control (Type: None): Patients are discharged the day after PCI
- 2 Study group (Type: None): Patients will be discharged 4-6 hrs after PCI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness Practice in Pregnancy As an Intervention to Decrease Prenatal Stress During the COVID-19 Pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women between 16w0d-26w6d gestation with a single gestation who have had a confirmed dating ultrasound~   a. Only women with singleton gestations will be included because multiple gestation pregnancies introduce additional levels of stress and introduce confounding variables for the adverse composite pregnancy outcome that will be measured. As this is a study of pregnant patients, only women are included.~2. English speaking~   a. The mindfulness meditation trainings have been scripted and recorded in English. Thus, to understand the recordings and participate in the courses it is necessary for all participants to speak English.~3. Regular internet access through either phone, tablet or computer. a. Mindfulness meditations are administered via Zoom webinars so internet access is required. A proxy for internet access during recruitment will be confirmed by the inclusion of an email address in the electronic medical record (EMR).~Exclusion Criteria:~1. Multiple gestations. This has been chosen as an exclusion criteria to limit confounding variables for the secondary outcome of composite adverse pregnancy events.~2. Age \< 18

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Virtual Mindfulness intervention (Type: EXPERIMENTAL): Four weekly group Zoom webinars with a 15-20 minute pre-recorded meditation
- Standard of Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: OpSens PRIME CLASS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is at least 18 years old~* Subject has a degenerative aortic stenosis with mean valvular gradient ≥40 mmHg~* Subject has a formal heart-team indication for TAVR~* Subject has one or more stable coronary stenosis lesions 30-90% by visual estimation, in a vessel over 2 mm in diameter, and which is amenable for pressure-wire analysis~* Subject agrees to participate in the study and is able to sign the informed consent form~Exclusion Criteria:~* Subject is unable to provide informed consent~* Subject has asthma or acute bronchospasm~* Subject has unstable angina or myocardial infarction~* Subject meets any contraindication in the applicable OptoWire IFU~* Subject is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dPR and FFR (Type: None): Subjects with aortic stenosis who are considered for TAVR will undergo a physiological assessment and prediction of ischemic coronary lesions pre- and post-TAVR by using Opsens non-hyperemic dPR and/or Opsens FFR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intrathoracic Pressure Regulation on Decreased Cerebral Perfusion (4hour)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* intubated and mechanically ventilated on a volume controlled mode~* head injury or other intracranial pathology and compromised cerebral perfusion~* arterial line in place or alternative with continuous pressure monitoring~* SpO2 ≥90%~* mean arterial pressure \>55~* admission to ICU or about to undergo neurosurgery with planned placement of an invasive intracranial pressure monitor~* inclusion presents no significant delays to planned emergent neurosurgery~* prior written informed consent~Exclusion Criteria:~* cardiac or pulmonary injury~* confirmed pneumothorax or hemothorax~* serious neck injury resulting in neck swelling with jugular venous compression~* evidence of ongoing uncontrolled bleeding~* respiratory disease such as COPD, interstitial lung disease, or other parenchymal or pulmonary vascular disease~* marked hypertension at time of device use defined as systolic blood pressure \>180 mmHg~* congestive heart failure~* women with positive serum or urine pregnancy test or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ITPR (Type: EXPERIMENTAL): Use of the ITPR for 240 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Assessment of Right Ventricular Contractility in Response to Sildenafil

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Significant pulmonary arterial hypertension (mean pulmonary artery pressure \> 25 mm Hg)~* Patients aged 4-18 years~* Routine cardiac catheterization clinically indicated for deciding therapeutic treatment~* Informed assent/consent from patient/parent~Exclusion Criteria:~* Suprasystemic pulmonary artery pressures~* Evidence of right heart failure~* History of ventricular arrhythmia~* Known vascular access arrhythmia~* Contraindication to Sildenafil~* Concurrent inotropic / PDE administration~* Other medical, psychological or social circumstances which complicate a regular participation in the study, and/or increase the risk for the patients themselves~* No consent/assent~* Pregnancy or unwillingness to comply with contraceptive advice

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Neuromuscular Electrical Stimulation (NMES) for Dysphagia in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female.~* Meet diagnostic criteria for dysphagia symptoms using the NOMAS and a VFSS.~* Infants with intraventricular hemorrhage (IVH) and hypoxic events can be included.~* Infants taking less than 5-10% of target volume by mouth between the ages of 36-42 weeks PCA.~* Multiple swallows to clear bolus following suck that includes a desaturation \<80% and bradycardia \<80 bpm.~* Apnea spells during feeds.~* Aspiration or penetration by VFSS~Exclusion Criteria:~* Known neurologic or neurodegenerative disorders.~* Chromosomal anomalies and syndromes.~* Cleft lip or palate.~* Birth defects.~* Unresolved cutaneous rash at the area of electrode placement.~* Medical condition that is a contraindication to NMES.

- Gender: ALL
- Minimum Age: 36 Weeks
- Maximum Age: 42 Weeks
- Healthy Volunteers: f

Study Arms:
- VitalStim (Type: EXPERIMENTAL): This group will be assigned to the active VitalStim unit.
- Sham VitalStim (Type: SHAM_COMPARATOR): This group will be assigned to the sham VitalStim unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. 18 - 65 years of age~2. English speaking~3. Diagnostic and Statistical Manual- IV diagnosis of schizophrenia or schizoaffective disorder based on Structured Clinical Interview for Diagnostic and Statistical Manual-IV (SCID)~4. Symptomatic stability confirmed by clinical staff in the 8 weeks prior to the study~5. No changes in antipsychotic medication within the last 8 weeks~6. No change in antipsychotic dose in in last 4 weeks.~Exclusion criteria are:~1. Unable to provide informed consent~2. Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of alcohol/substance dependence~3. Recent history of gastrointestinal bleeding or ulceration~4. Recent history of gallstones and/or bile duct obstruction~5. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease)~6. Known intolerance to turmeric, curcumin, or curry~7. Pregnancy or breast-feeding~8. Current use of anti-platelet, anti-coagulant, glucocorticoid, immunosuppressants~9. Daily use of non-steroidal anti-inflammatory use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Curcumin 1800mg (Type: EXPERIMENTAL): curcumin capsule 600mg taken 3 times per day for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsule taken 3 times per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed recurrent ovarian epithelial cancer after first line chemotherapy, unless clear evidence of clinically progressive disease~* Must have received prior first line chemotherapy consisting of at least 4 courses of either cisplatin or carboplatin~  * At least 12 months since prior chemotherapy~* Measurable disease by clinical exam or diagnostic laparoscopy~  * At least one lesion greater than 1 cm in diameter~* No leptomeningeal or brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.25 times upper limit of normal (ULN)~* SGPT less than 2 times ULN~Renal:~* Creatinine less than 1.6 mg/dL OR~* Creatinine clearance greater than 40 mL/min~Other:~* No peripheral neurotoxicity greater than grade 2~* No psychological, familial, sociological, or geographical condition that would preclude study~* No complete bowel obstruction~* No other malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No more than 1 prior regimen of chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cross-education for Proximal Humerus Fracture Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Proximal humerus fracture \<2 weeks old~* Isolated injury sustained~* After low-energy trauma (i.e. simple fall from standing; high-energy injuries often have concurrent injuries or require surgery)~* For conservative management~* English speaking/understanding (for the duration of the pilot; the full study could be extended to include use of translated information and interpreters)~* Independent living at the time of injury (i.e. not institutionalised, so measure of function is a relevant outcome)~Exclusion Criteria:~* Concurrent injuries~* Fractured shaft of or distal humerus~* Pathological fracture (due to cancer) or fracture as a result of high energy trauma~* Previous fracture or pathology to either side~* History of upper extremity neurological problems (e.g. multiple sclerosis, stroke, Parkinson's disease, vestibular disorders, reflex neuropathy)~* Diagnosis of dementia/other cognitive impairment~* Not able to attend the Trust's outpatient departments for rehabilitation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
- Experimental (Type: EXPERIMENTAL): Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: C-MAC VS Clinical Observation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients for elective and emergency surgery who have at least one predictor for difficult airway management, which are: Mallampati score \>2, mouth opening \<4cm, thyromental distance \<6cm, head \& neck movements \<90°, short neck, reduced reclination.~* Patients who signed general research consent in Switzerland.~Exclusion Criteria:~* Patients under the age of 18 years~* Personnel at the study site not available of not sufficient ted in the device.~* Expected impossible mask ventilation~* High risk of aspiration (requiring rapid sequence induction intubation)~* Intracranial surgery~* Limited knowledge of German language or refusing general consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or more~* acute myeloid leukemia or myelosysplasia undergoing induction remission or consolidation therapy~* allogeneic stem cell transplant recipients~Exclusion Criteria:~* prior invasive mould infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- preemptive (Type: NO_INTERVENTION): Patients with persistent fever and neutropenia despite appropriate antibacterial therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* At the time of dosing, participants must be 6 months to 12 years of age~* Males and females with diagnosis of severe MMA meeting all the following;~  1. Isolated MMA with genetically confirmed, pathogenic mutations in the MMUT gene~ 2. Screening serum/plasma methylmalonic acid level of \>100 µmol/L~ 3. One or more of the following considered by the PI to be MMA-related: (i) An unscheduled ER visit, hospitalization or requirement for sick day diet in the year prior to screening visit (ii) Developmental delay, movement disorder, optic neuropathy or feeding disorder with tube feeding requirement~ 4. Medically stable for the 2 months prior to the start of screening~Exclusion Criteria:~* Participants with organic acidemias other than isolated MMA, or with any other causes of hyperammonemia~* Having received MMA-targeted gene therapy or nucleic acid therapy~* Participants on insulin or high dose hydroxocobalamin (\> 1 mg/day OHB12 parenteral)~* Kidney or liver transplant, including hepatocyte cell therapy~* Estimated glomerular filtration rate (eGFR) of \< 60 mL/min/1.73 m2 based on age appropriate equations, or ongoing dialysis for renal disease~* Participant tests positive for anti-rAAV-LK03-neutralizing antibodies

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Dose Level 1 Part A (Type: EXPERIMENTAL): 3 year-olds to 12 year-olds
- Dose Level 1 Part B (Type: EXPERIMENTAL): 6 month to 2 year-olds
- Dose Level 1 Part C (Type: EXPERIMENTAL): 6 month to 12 year-olds
- Dose Level 2 Part A (Type: EXPERIMENTAL): 3 year-olds to 12 year-olds
- Dose Level 2 Part B (Type: EXPERIMENTAL): 6 month to 2 year-olds

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 6 to 18 years,~* Must be able to swallow tablets, and~* Biopsy proven ulcerative colitis~Exclusion Criteria:~* Allergy or hypersensitivity to Mesalamine or other salicylates~* Use of rectal medications

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Asacol once a day dosing (Type: EXPERIMENTAL): Asacol total dose in mg/kg given once a day
- Asacol BID/TID dosing (Type: ACTIVE_COMPARATOR): Asacol total dose split BID or TID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* With suspected advanced ovarian cancer or genetic predisposition to malignant neoplasm of the ovary~* Planned surgery~* Have a uterus and no history of tubal occlusion~Exclusion Criteria:~* Unable to speak English~* Unable to provide informed consent~* Prior hysterectomy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (pap smear, uterine lavage, tumor sample) (Type: EXPERIMENTAL): Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues